About BRII-B Company

Tengsheng Pharmaceuticals is a leading biotechnology company dedicated to developing innovative therapies in fields where medical needs are highly unmet, especially infectious diseases where traditional treatment options are limited and social characteristics persist. Since its establishment in 2018, Tengsheng Pharmaceuticals's mission has been to address public health challenges through groundbreaking scientific innovation and critical patient insight. Tengsheng Pharmaceutical specializes in infectious diseases and is the first to launch a clinical project for hepatitis B virus infection. Through in-house research and cooperation with leading global companies, we aim to provide more effective and safe treatment solutions for patients in China and around the world. The core of our HBV product portfolio is our strong assets, including the proprietary therapeutic vaccine BRII-179, siRNA BRII-835 (elebsiran), and the neutralizing antibody BRII-877 (tobevibart). Through ongoing joint research and strategic partnerships, we aim to significantly improve the functional cure rate of HBV. Based on key data results from recent years (particularly 2023) and upcoming BRII-179 intellectual property and technology transfers, we have strengthened our leading position and are planning to launch additional combination therapy research in 2024. Additionally, we have global rights, including BRII-693, and are actively seeking strategic partnerships, and continue to work on clinical-stage projects targeting multidrug-resistant and broadly resistant gram-negative bacterial infections. We are also exploring cooperation opportunities for drug candidates for the treatment of human immunodeficiency virus and postpartum depression/major depression to ensure the accelerated development of our broad product portfolio. Exploring HBV remains a top priority. Strategically optimizing our organizational structure, Tengsheng Pharmaceuticals has realigned its executive team to maximize internal resource allocation and drive sustainable long-term growth. With experienced industry veterans on board, we will be able to refine our R&D strategy and place a strong emphasis on platforms and disease areas that are consistent with our pipeline interests, priorities, and strategic goals. Looking ahead, the company is preparing to launch late-stage clinical trials for its HBV functional healing program, prioritizing scientific differentiation, shortening the time to commercialize, and fully exploiting the best-in-class potential of our project. Additionally, we will actively seek external collaboration to advance clinical development of our MDR/XDR, HIV, and CNS programs.